Scientific Resources

Our next-generation diagnostic assays have generated novel insights across a broad range of clinical applications.

Access our presentations, publications, and more to see how we’re unlocking the full potential of precision genomics.

High rates of undetectable MRD by PhasED-Seq on interim and end of treatment timepoints in untreated advanced stage CHL treated with pembrolizumab + AVD
December 12, 2024 | Poster
The role of MRD-based recurrence detection in early stage lung and breast cancer
November 20, 2024 | Video
Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
September 16, 2024 | Poster
Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell Malignancies
August 9, 2024 | Manuscript
Response-adapted treatment with mosunetuzumab with or without obinutuzumab andpolatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: interim resultsand PhasED-Seq MRD analysis
June 17, 2024 | Poster
Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC).
June 5, 2024 | Poster